EC Number   |
|---|
   3.4.22.56 | - |
| 3.4.22.56 | caspase-3 in complex with beta-strand urazole ring-containing irreversible peptidomimetic inhibitor compound-1, vapor diffusion, at 4°C, from 0.005 ml drops containing equal volumes of 16% ethanol, 0.1 M Tris buffer, pH 7.8, and the protein complex solution, X-ray diffraction structure determination and analysis at 2.0 A resolution, molecular replacement |
| 3.4.22.56 | co-crystals of the complex between recombinant human caspase-3 and azapeptide epoxide inhibitors are grown from hanging drops |
| 3.4.22.56 | complex of caspase-3 with (S)-5-[[5-(1-carboxymethyl-2-oxo-ethylcarbamoyl)pyridin-2-ylmethyl]sulfamoyl]-2-hydroxy-benzoic acid and (S)-5-[[5-[1-carboxylmethyl-3-(2-chlorobenzylsulfanyl)-2-oxo-propylcarbamoyl]thiophen-2-ylmethyl]sulfamoyl]-2-hydroxy-benzoic acid, hanging drop vapor diffusion method |
| 3.4.22.56 | crystal structure of recombinant enzyme in complex with acetyl-Asp-Val-Ala-Asp fluoromethyl ketone, hanging and sitting drop vapor diffusion method |
| 3.4.22.56 | in complex with inhibitor Asp-Glu-Val-Asp-chloromethylketone |
| 3.4.22.56 | in complex with inhibitors acetyl-Asp-Glu-Val-Asp-aldehyde, acetyl-Val-Asp-Val-Ala-Asp-aldehyde, acetyl-Asp-Met-Gln-Asp-aldehyde |
| 3.4.22.56 | recombinant enzyme in complex with inhibitors Ac-IEPD-Cho, Ac-WEHD-Cho, Ac-YVADCho, and Boc-D(OMe)-fluoromethyl ketone, caspase-3 is incubated at room temperature with the inhibitor at 10 to 20fold molar excess, followed by crystallization via the hanging-drop vapor diffusion method, 0.001 ml of 4 mg/ml protein in solution is mixed with an equal volume of mother liquid containing 100 mM sodium citrate, 5% glycerol, 10 mM DTT, and 14-18% PEG 6000, pH 6.5, 24 h at room temperature, X-ray diffraction structure determination and analysis at 1.9-2.6 A resolution, molecular replacement, modelling, overview |
